An Acid-Sensitive Nanofiber Conjugate Based on a Short Aromatic Peptide for Targeted Delivery of Doxorubicin in Liver Cancer

References

• Goncalves M, Mignani S, Rodrigues J, Tomas H. A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. J Controlled Release. 2020;317:347–374. doi:10.1016/j.jconrel.2019.11.016
   PubMed Web of Science ®Google Scholar
• Liu C, Ma XR, Zhuang J, Liu LJ, Sun CG. Cardiotoxicity of doxorubicin-based cancer treatment: what is the protective cognition that phytochemicals provide us? Pharmacol Res. 2020;160:105062. doi:10.1016/j.phrs.2020.105062
   PubMed Web of Science ®Google Scholar
• Agudelo D, Bourassa P, Berube G, Tajmir-Riahi HA. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: structural models and antitumor activity. J Photochem Photobiol B-Biol. 2016;158:274–279. doi:10.1016/j.jphotobiol.2016.02.032
   PubMed Web of Science ®Google Scholar
• Li D, Yang Y, Wang S. Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biol. 2021;46:102089. doi:10.1016/j.redox.2021.102089
   PubMed Web of Science ®Google Scholar
• Hu C, Zhang X, Wei WY, et al. Matrine attenuates oxidative stress and cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity via maintaining AMPK alpha/UCP2 pathway. Acta Pharmaceutica Sinica B. 2019;9(4):690–701. doi:10.1016/j.apsb.2019.03.003
   PubMed Web of Science ®Google Scholar
• Cui H, Huan ML, Ye WL, et al. Mitochondria and nucleus dual delivery system to overcome DOX resistance. Mol Pharm. 2017;14(3):746–756. doi:10.1021/acs.molpharmaceut.6b01016
   PubMed Web of Science ®Google Scholar
• Duan HX, Liu YH, Gao ZG, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharmaceutica Sinica B. 2021;11(1):55–70. doi:10.1016/j.apsb.2020.09.016
   PubMed Web of Science ®Google Scholar
• He YM, Lei L, Cao J, et al. A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. Sci Adv. 2021;7(6). doi:10.1126/sciadv.aba0776
   Web of Science ®Google Scholar
• Liu J, Chen Q, Feng L, Liu Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today. 2018;21:55–73. doi:10.1016/j.nantod.2018.06.008
   Web of Science ®Google Scholar
• Zhang YJ, Sun T, Jiang C. Biomacromolecules as carriers in drug delivery and tissue engineering. Acta Pharmaceutica Sinica B. 2018;8(1):34–50. doi:10.1016/j.apsb.2017.11.005
   PubMed Web of Science ®Google Scholar
• Takano S, Islam W, Nakazawa K, Maeda H, Sakurai K, Fujii S. Phosphorylcholine-grafted molecular bottlebrush-doxorubicin conjugates: high structural stability, long circulation in blood, and efficient anticancer activity. Biomacromolecules. 2021;22(3):1186–1196. doi:10.1021/acs.biomac.0c01704
   PubMed Web of Science ®Google Scholar
• Quader S, Cabral H, Mochida Y, et al. Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. J Controlled Release. 2014;188:67–77. doi:10.1016/j.jconrel.2014.05.048
   PubMed Web of Science ®Google Scholar
• Li W, Fu J, Ding Y, Liu D, Jia N. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency. Acta Biomaterialia. 2019;96:456–467. doi:10.1016/j.actbio.2019.06.051
   PubMed Web of Science ®Google Scholar
• Guo FY, Yu N, Jiao YL, et al. Star polyester-based folate acid-targeting nanoparticles for doxorubicin and curcumin co-delivery to combat multidrug-resistant breast cancer. Drug Deliv. 2021;28(1):1709–1721. doi:10.1080/10717544.2021.1960926
   PubMed Web of Science ®Google Scholar
• Toy R, Bauer L, Hoimes C, Ghaghada KB, Karathanasis E. Targeted nanotechnology for cancer imaging. Adv Drug Deliv Rev. 2014;76:79–97. doi:10.1016/j.addr.2014.08.002
   PubMed Web of Science ®Google Scholar
• Petrov RA, Mefedova SR, Yamansarov EY, et al. New small-molecule glycoconjugates of docetaxel and GalNAc for targeted delivery to hepatocellular carcinoma. Mol Pharm. 2021;18(1):461–468. doi:10.1021/acs.molpharmaceut.0c00980
   PubMed Web of Science ®Google Scholar
• D’Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J Controlled Release. 2015;203:126–139. doi:10.1016/j.jconrel.2015.02.022
   PubMed Web of Science ®Google Scholar
• Sharma R, Porterfield JE, An HT, et al. Rationally designed galactose dendrimer for hepatocyte-specific targeting and intracellular drug delivery for the treatment of liver disorders. Biomacromolecules. 2021;22(8):3574–3589. doi:10.1021/acs.biomac.1c00649
   PubMed Web of Science ®Google Scholar
• Naguib MJ, Kamel AM, Negmeldin AT, Elshafeey AH, Elsayed I. Molecular docking and statistical optimization of taurocholate-stabilized galactose anchored bilosomes for the enhancement of sofosbuvir absorption and hepatic relative targeting efficiency. Drug Deliv. 2020;27(1):996–1009. doi:10.1080/10717544.2020.1787557
   PubMed Web of Science ®Google Scholar
• Liang J, Xuan M, Wu W, Li J. GSH-responsive nanofibrous prodrug formed by a short naphthylacetic acid-terminated peptide for 6-mercaptopurine delivery. J Drug Deliv Sci Technol. 2021;65:102691. doi:10.1016/j.jddst.2021.102691
   Web of Science ®Google Scholar
• Ovais M, Mukherjee S, Pramanik A, et al. Designing stimuli-responsive upconversion nanoparticles that exploit the tumor microenvironment. Adv Mater. 2020;32(22):2000055. doi:10.1002/adma.202000055
   Web of Science ®Google Scholar
• Cheng H, Zhu J, Xu X, et al. Activable cell-penetrating peptide conjugated prodrug for tumor targeted drug delivery. ACS Appl Mater Interfaces. 2015;7:16061. doi:10.1016/j.addr.2016.06.015
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Salehi D, Mahdipoor P, et al. Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. Eur J Med Chem. 2021;226:113836. doi:10.1016/j.ejmech.2021.113836
   PubMed Web of Science ®Google Scholar
• Alam Khan S, Jawaid Akhtar M. Structural modification and strategies for the enhanced doxorubicin drug delivery. Bioorg Chem. 2022;120:105599. doi:10.1016/j.bioorg.2022.105599
   PubMed Web of Science ®Google Scholar
• Sohail M, Sun Z, Li Y, Gu X, Xu H. Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy. Expert Rev Anticancer Ther. 2021;21(12):1385–1398. doi:10.1080/14737140.2021.1991316
   PubMed Web of Science ®Google Scholar
• Alas M, Saghaeidehkordi A, Kaur K. Peptide-drug conjugates with different linkers for cancer therapy. J Med Chem. 2021;64(1):216–232. doi:10.1021/acs.jmedchem.0c01530
   PubMed Web of Science ®Google Scholar
• Hao T, Fu Y, Yang Y, et al. Tumor vasculature-targeting PEGylated peptide-drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis. Eur J Med Chem. 2021;219:113430. doi:10.1016/j.ejmech.2021.113430
   PubMed Web of Science ®Google Scholar
• Deng X, Mai R, Zhang C, et al. Discovery of novel cell-penetrating and tumor-targeting peptide-drug conjugate (PDC) for programmable delivery of paclitaxel and cancer treatment. Eur J Med Chem. 2021;213:113050. doi:10.1016/j.ejmech.2020.113050
   PubMed Web of Science ®Google Scholar
• Fang Y, Wang H. Molecular engineering of peptide-drug conjugates for therapeutics. Pharmaceutics. 2022;14(1):212. doi:10.3390/pharmaceutics14010212
   PubMed Web of Science ®Google Scholar
• Zhang Y, He P, Zhang P, Yi X, Xiao C, Chen X. Polypeptides-drug conjugates for anticancer therapy. Adv Healthc Mater. 2021;10(11):e2001974. doi:10.1002/adhm.202001974
   PubMed Web of Science ®Google Scholar